Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Direct and specific thymidylate synthase inhibitors, such as raltitrexed ('Tomudex', formerly ZD1694), provide a promising new therapeutic approach to the treatment of advanced colorectal cancer. Two international phase III trials (studies 3 and 12) compared raltitrexed (3 mg/m2) with 5-fluorouracil plus low-dose leucovorin or plus high-dose leucovorin, respectively. Study 3 included a 15.5-month follow-up for efficacy and a 26-month follow-up for survival. Results of an interim analysis for study 12 are presented. Objective tumour response rates for each treatment group were comparable in both studies 3 (P=0.48) and 12 (P=0.896). The median time to progression was similar between treatments in study 3 (P=0.44), but was significantly longer for 5-fluorouracil + leucovorin compared with raltitrexed in study 12 (5.1 versus 3.9 months, P=0.005). The median survival (raltitrexed versus 5-fluorouracil + leucovorin) was comparable in both studies 3 (10.1 versus 10.2 months, P=0.42) and 12 (10.7 versus 11.8 months, P=0.36). Palliative benefits were similar between treatments in both studies. A third phase III trial (study 10), carried out in North America, demonstrated a statistically significantly longer median survival for 5-fluorouracil + leucovorin compared with raltitrexed (12.7 months versus 9.7 months; P=0.01). However, the possible unfamiliarity of the clinicians with raltitrexed and the early discontinuation of a 4 mg/m2 raltitrexed arm due to toxicity may have led to an unconscious investigator bias in this trial, leading to a non-protocol-led withdrawal of patients from the study. Overall, raltitrexed is comparable with standard 5-fluorouracil + leucovorin therapy in terms of response rates and overall survival, and has a more convenient dose schedule.

Original publication

DOI

10.1097/00001813-199708002-00003

Type

Conference paper

Publication Date

08/1997

Volume

8 Suppl 2

Pages

S11 - S15

Keywords

Animals, Antimetabolites, Antineoplastic, Clinical Trials, Phase III as Topic, Colorectal Neoplasms, Quinazolines, Thiophenes